profit from every $100 of sales.
$0$100
Celularity
We have no price for Celularity since 17 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00+533.33% today
-89.1% since Oct 13, 25
1-year low $0.001-year high $0.02
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Celularity vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Celularity | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Celularity's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.01
- -0.6×
- 0.8×
- –
- –
- -6,636.9%
- -407.2%
- 0.0%
Profitability
- 76.0%
- -230.9%
- -345.4%
- -292.4%
- -151.1%
- -712.8%
- 411.5%
- -85.5%
- -230.7%
- 56.6%
Growth
- +5.6%
- –
- −102.0%
- –
- +19.1%
Financial health
- -0.4×
- -1.07
- 38.1%
- -9.1×
- 0.15
- 0.15
- 0.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 867
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.85 | -1.50 | +43.3% |
| Nov 14, 2025 | -0.88 | -1.50 | +41.6% |
| Aug 29, 2025 | -1.02 | – | – |
| Jun 30, 2023 | -0.00 | – | – |
| Mar 31, 2023 | -0.00 | – | – |
| Dec 31, 2022 | 271,488.89 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
29No pass
Benjamin Graham
0No pass
Philip Fisher
30No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
22No pass
Questions about Celularity
Is Celularity a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Celularity AI analysis
What does Celularity do?
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It is in Biotechnology.
Does Celularity pay a dividend?
No. Celularity does not pay a dividend at the moment.
Who are Celularity's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Celularity's.
Prices: daily closes to Jul 17, 2026. Fundamentals: company reports via invest-like data.